ClinicalTrials.gg
RecruitingNCT06080841Updated May 25, 2025

Curcumin Supplementation in Cervical Cancer

An interventional study of Curcumin and Curcumin + Piperine in Locally Advanced Cervical Cancer, sponsored by National Institute of Cancerología. Recruiting at 1 site in Mexico. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by National Institute of Cancerología · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Apr 2023, registered Sep 2023).
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Uterine Cervical Neoplasms by National Institute of Cancerología — 8 open to participants now, 8 under way, 1 of them phase 3. Uterine Cervical Neoplasms · National Institute of Cancerología.

Planned enrollment
11th of 15
30 · median 84
Started
2023
the only one that year
No phase
8 of 18
5 open now
Registered
17th of 18
by date

Among the 18 studies in Uterine Cervical Neoplasms by National Institute of Cancerología, this one is the 11th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2023, is one of 8 with no phase, and was the 17th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

8 of the 18 studies in Uterine Cervical Neoplasms by National Institute of Cancerología are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Uterine Cervical Neoplasms by National Institute of Cancerología, or all of them as a file.
02

Study summary

Brief Summary.

The goal of this pilot study is to learn about the effect of curcumin supplementation in locally advanced cervical cancer patients. The main questions it aims to answer are:

  • Does curcumin supplementation increase the levels of p53 and apoptosis in tumor cells from cervical cancer patients?
  • At which dose of curcumin supplementation is the broader effect observed for p53 expression and apoptosis in tumor cells from cervical cancer patients?
  • Are all doses safe for supplementation?

Participants will be asked to take curcumin tablets throughout their cancer treatment. Researchers will compare 6 different groups, each group will receive a different dose of curcumin with or without piperin, to see the dose with the broader effect and safety of curcumin supplementation:

  1. 1 g of curcumin
  2. 1 g of curcumin + piperine
  3. 3 g of curcumin
  4. 3 g of curcumin + piperine
  5. 6 g of curcumin
  6. 6 g of curcumin + piperine
Read the detailed description

BACKGROUND Cervical cancer (CC) continues to be a major public health problem in Mexico. Today more than 4,000 women die each year from this disease, which requires implementing strategies that can improve current treatments, particularly for locally advanced disease. Today it is clear that persistent high-risk Human Papillomavirus infections are the main risk factor for developing CC. At the National Cancer Institute of Mexico (INCan), 80% of patients are diagnosed at locally advanced stages (IB3-IVA). The standard treatment for these stages is concomitant chemoradiotherapy (CCRT) followed by brachytherapy (BT).

p53 restricts tumor growth, promoting cell death and decreasing cell viability. Activation of p53 is vital for CCRT-induced cytotoxicity, while inactivation of p53 has been associated with resistance or insensitivity to treatment. Different nutraceuticals such as berberine and curcumin can reactivate endogenous p53 and exhibit its effects in CC. The E6 oncoprotein inactivates the p53 pathway in CC; therefore, the restoration of p53 may be a promising therapeutic strategy.

The health benefits associated with consuming fruits, vegetables, teas, and spices are due to the presence of phytochemicals. Diets characterized by regular consumption of fruits and vegetables have been associated with a decrease in the risk of CC. A particular group of phytochemicals of interest is polyphenols. The polyphenol curcumin is considered safe and non-toxic by the FDA (Food and Drug Administration), and its administration causes minimal low-grade adverse effects (mainly grade 1 diarrhea). Based on clinical trials' safety and toxicity profile, a dose of up to 8000 mg/day of curcumin can be considered safe.

The current information on the bioavailability of phytochemicals continues to be limited, which places great importance on the exploration of polyphenols as possible new therapeutics. However, the low bioavailability and complex metabolism linked to polyphenols make it difficult to recommend a dose for daily consumption. The addition of piperine to curcumin supplementation has been demonstrated to increase absorption in the intestine.

Different biological effects have been associated with curcumin supplementation in cancer patients. Patients with pancreatic cancer received oral administration of curcumin at a dose of 8 g/day for eight months in combination with gemcitabine, which was well tolerated and showed an improvement in overall survival. Curcumin activity was evaluated in patients with metastatic colon cancer, finding that it was safe and tolerable in combination with FOLFOX.

In locally advanced CC patients, the effect that curcumin has on the expression of p53 in tumor cells has not been investigated, although in vitro studies have demonstrated its effect on the inhibition of oncoproteins, such as E6, and the consequent stabilization of p53, which makes CC cells more susceptible to being destroyed.

The present pilot study seeks to demonstrate that curcumin supplementation will regulate molecular markers, such as p53 and apoptosis in tumor cells, which could provide the basis to study further whether this modulation by curcumin leads to a greater susceptibility of the tumor to standard cancer treatment and, therefore, a better response to treatment.

METHODS The work will be carried out at the National Cancer Institute of Mexico (INCan) in patients with locally advanced CC. Six supplementation groups will be included; in three groups, curcumin will be administered in tablets in oral doses of 1, 3, and 6 g / day respectively, and in the other three groups, curcumin will be administered in tablets in oral doses of 1, 3, and 6 g / day respectively plus 5 mg of piperine/g of curcumin (to facilitate the absorption of curcumin).

Invitation to the study protocol: Diagnosis will be confirmed in the INCan Functional Gynecology Oncology Unit. The corresponding studies are carried out to corroborate that the patient meets the inclusion criteria. On the day of the invitation to the patient, the patient will be explained what the study consists of, and the Informed Consents will be read. If the patient agrees to participate and signs the consent, she will be assigned to the corresponding curcumin dose group.

The patients will be followed for four visits throughout the study: (1) 2 weeks before the beginning of treatment; (2) at the beginning of CRT; (3) at the third cycle of CRT; and (4) at BT.

Patients will be evaluated in 4 visits:

  • Visit 1: Indications for a standard diet will be given according to the patient's requirements. Curcumin will be provided to the patient, and instructions for its use will be given according to the group to which she has been assigned. Urine and serum samples will be collected. A cervical swab sample will be obtained.
  • Visit 2: The day of initiation of treatment with concomitant CRT. Feces, urine, and serum samples will be collected. A cervical swab sample will be obtained.
  • Visit 3: Once the 3 CRT cycles have been completed. Feces, urine, and serum samples will be collected. A cervical swab sample will be obtained.
  • Visit 4: When starting treatment with BT. Urine and serum samples will be collected.

Biological samples:

Cervicovaginal cytologies will be taken at each visit. The samples will be analyzed by flow cytometry to quantify p53 positive cells and annexin will be used to identify apoptosis.

Adherence to supplementation will be monitored, bioavailability will be investigated, gastrointestinal toxicity determined, and the safety of supplementation evaluated. Gastrointestinal symptoms will be classified at each visit during treatment according to common toxicity criteria (CTCAE v. 5). Liver function tests, renal function tests, blood chemistry, and hematic biometry will be monitored to assess curcumin supplementation safety. Stool, urine, and serum samples will be taken, from which the bioavailability of curcumin will be assessed by liquid chromatography-electrospray ionization-mass spectrometry. A comparative analysis of these variables will be made between the different supplementation groups to establish the dose in which an impact on the expression of p53 and apoptosis is observed.

Analysis of data:

Data will be analyzed using Statistica software, and graphs will be made in GraphPad Prism. A single-factor repeated measures analysis will be performed with repeated measures across all treatments. The analysis plan will consist of:

  • Normality test. The Shapiro-Wilk test will be performed to know if the variables' distribution is normal.
  • Descriptive analysis. The distribution of the quantitative independent variables will be determined using the Kolmogorov-Smirnov test. The mean ± standard deviation will be reported for variables with normal distribution or median with 25th and 75th percentiles for variables with free distribution.
  • One-way or two-way ANOVA will be performed to determine the significance of differences between groups, followed by Tukey's test for the significance of differences. Confidence intervals will be constructed at 95%, and a value will be declared statistically significant when p is \<0.05.
  • Multivariate analysis. The following tests will be used to determine if there are differences between the patients who were supplemented with the different doses of curcumin and those who also received piperine:

    • Student's T test for quantitative variables with normal distribution.
    • Mann Whitney U test for quantitative variables with free distribution or ordinal variables.
    • Chi-square test for dichotomous and polytomous variables.

EXPECTED RESULTS AND PERSPECTIVES The investigators expect that curcumin supplementation will stabilize the expression of p53 and increase the apoptosis of tumor cells. The investigators also expect that piperine will increase its absorption. In addition, a dose in humans associated with the expression of p53 has not been reported, so this study will allow the identification of the dose that favors said expression in humans. In addition to its molecular effect, due to its antioxidant properties, the investigators expect that patients will improve gastrointestinal symptoms associated with treatment with CCRT.

03

Conditions studied

  • Locally Advanced Cervical Cancer

Keywords

  • curcumin
  • locally advanced cervical cancer
  • p53
  • apoptosis
  • chemoradiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understanding the nature of the study and giving a written consent report.
  2. Women > 18 years old.
  3. performance status: 0-2.
  4. Be willing and able to comply with scheduled visits, treatment plans, and laboratory tests.
  5. Patients with a histological cervical cancer diagnosis: squamous cell, adenosquamous, adenocarcinoma, and glassy cell carcinoma.
  6. Classified with clinical stage IB3-IVA (FIGO 2018).
  7. Candidates to receive concomitant -RT followed by BT.
  8. With disease measurable by any imaging method (CT/MRI/PET-CT) according to v 1.1 criteria.
  9. Patients without prior treatment based on QT-RT.
  10. ≥ 10 g/dL.
  11. Leukocytes ≥ 4000/mm3.
  12. ≥ 100,000/mm3.
  13. Adequate liver function.

Exclusion criteria

Exclusion Criteria:

  1. Patients undergoing nutritional treatment or ingesting any dietary supplement, including those containing turmeric or turmeric derivatives, ginger, or rhizome of the turmeric family.
  2. Patients with uncontrolled intercurrent diseases, including active infections that contraindicate CT.
  3. Patients receiving concomitant treatment with an experimental drug.
  4. Patients with vesicovaginal or vesicorectal fistula are diagnosed.
  5. Patients with previous or concomitant except non-melanoma skin carcinoma.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Group 1

    1g of curcumin.

    Dietary Supplement: Curcumin

  • Experimental
    Group 2

    1 g curcumin + 5 mg piperine.

    Dietary Supplement: Curcumin + Piperine

  • Experimental
    Group 3

    3 g of curcumin.

    Dietary Supplement: Curcumin

  • Experimental
    Group 4

    3 g curcumin + 15 mg piperine.

    Dietary Supplement: Curcumin + Piperine

  • Experimental
    Group 5

    6 g of curcumin.

    Dietary Supplement: Curcumin

  • Experimental
    Group 6

    6 g curcumin + 15 mg piperine.

    Dietary Supplement: Curcumin + Piperine

Interventions

  • Dietary supplementCurcumin

    Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin. They will be instructed to consume orally 1 capsule with breakfast for group 1, 1 capsule with each meal for group 3, and 2 capsules with each food for group 5.

  • Dietary supplementCurcumin + Piperine

    Drug pages: CurcuminStudies of CurcuminCurcumin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PiperineStudies of PiperinePiperine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin additioned with 5 mg of piperine. They will be instructed to consume orally 1 capsule with breakfast for group 2, 1 capsule with each meal for group 4, and 2 capsules with each meal for group 6.

06

What researchers measure

Primary outcomes

  1. p53 expression

    Using the liquid-based cervicovaginal cytology samples, p53 will be quantified by the ELISA method. p53 positive cells will be quantified through flow cytometry.

    Time frame: Through study completion, an average of 3 years

  2. Frequency of Apoptosis

    A conjugate of Annexin V and fluorophore will be used to determine apoptosis in cells from liquid-based cytology, through flow cytometry. The number of apototic cells (positive for Annexin V) will be quantified, and the percentage will be calculated.

    Time frame: Through study completion, an average of 3 years

Secondary outcomes

  1. Frequency of Gastrointestinal toxicity

    Symptoms of gastrointestinal toxicity will be recorded and graded at each visit during treatment according to the common toxicity criteria of adverse events (CTCAE v.5). Frequency and severity will be assessed.

    Time frame: Through study completion, an average of 3 years

  2. Bioavailability of curcumin

    To determine the bioavailability of curcumin, blood, fecal, and urine samples will be obtained. It is proposed to use Chen's method (1997) with some modifications to determine the total amount of bioactive, including lupeol and polyphenols free and in conjugated form; the methodology will depend on the corresponding biological sample, by ultra-high resolution liquid chromatography with chemical ionization at atmospheric pressure coupled or electrospray ionization with MS (UPLC-API or ESI-MS/MS)

    Time frame: Through study completion, an average of 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The final report will be shared, and other information or data will be shared upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2025, 32 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 32 months is close to that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Oct 12, 2023
StartActual
Apr 19, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Mar 2026
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06080841
Lead sponsor
National Institute of Cancerología
Collaborators
Sabinsa Corporation
Responsible party
Sponsor
First posted
Oct 12, 2023
Start date
Apr 19, 2023
Primary completion
Dec 2025 (estimated)
Completion
Mar 2026 (estimated)
Last update
May 25, 2025

Study contacts

Denisse Castro-Eguiluz, RDN, PhD
Contact
adcastro@conahcyt.mx
+525541940650
Alejandro García Carrancá, PhD
Contact
carranca@biomedicas.unam.mx
+525555086910
Denisse Castro, RDN, PhD
principal investigator · Conacyt / National Cancer Institute of Mexico

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Curcumin · Piperine

Start the discussion